18:00 · Daily read
One brief a day.
Every evening at 18:00 Europe/Lisbon, the desk synthesises the day's news into a single editorial. 3–5 themes, named mechanisms, one thing to watch tomorrow. Individual items still live in the news feed.
Thursday, 16 July 2026
Capital Concentrates as Regulators Demand Outcomes, Not Hype
The industry is simultaneously channeling investment into fewer, larger bets while global regulators and payers pivot to demand hard evidence and clinical outcomes, exposing the fragile economics of ventures that lack robust, demonstrable impact.
Funding & M&A · Policy & Regulation · Clinical AI · Pharma
Wednesday, 15 July 2026
When AI Enters Clinical Practice: Benefits, Backlash, and Bad Actors
This week's news lays bare AI's complex entry into healthcare, revealing a tension between ambitious adoption and growing scrutiny over its unchecked deployment, particularly as opaque algorithms face regulatory pushback and established players struggle with clinical differentiat
Clinical AI · Digital Therapeutics · Longevity & Diagnostics · Funding · Policy & Regulation · Biopharma
Tuesday, 14 July 2026
When AI Meets Inertia: Policy Gaps, Fund Friction, and Clinical Pushback
This week, regulatory landscapes are proving more reactive than proactive, with critical gaps emerging in AI governance and transparency, while established systems in funding and healthcare adoption continue to demonstrate significant inertial drag.
Policy · Clinical AI · Funding · Biopharma · Portugal Market
Friday, 10 July 2026
The Price of Access: M&A Valuations vs. Clinical Efficacy
Today's headlines underscore a deepening divergence between the market's enthusiasm for healthcare data access, demonstrated by significant M&A valuations, and the unyielding scientific rigor demanded for clinical approval, as evidenced by a major Phase 3 failure.
Clinical AI · Funding & M&A · Digital Therapeutics · Wearables · Biopharma